Ivan F Mcmurtry

List of Publications by Year in Descending Order

64 papers	5,179 citations	36 h-index	68 g-index
68 ext. papers	5,633 ext. citations	6.1 avg, IF	5.14 L-index

#	Paper	IF	Citations
64	Inhibition of Glucose-6-Phosphate Dehydrogenase Activity Attenuates Right Ventricle Pressure and Hypertrophy Elicited by VEGFR Inhibitor + Hypoxia. *Journal of Pharmacology and Experimental Therapeutics*, **2021**, 377, 284-292	4.7	6
63	Hypoxic activation of glucose-6-phosphate dehydrogenase controls the expression of genes involved in the pathogenesis of pulmonary hypertension through the regulation of DNA methylation. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2020**, 318, L773-L786	5.8	15
62	Pluripotent hematopoietic stem cells augment □adrenergic receptor-mediated contraction of pulmonary artery and contribute to the pathogenesis of pulmonary hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2020**, 318, L386-L401	5.8	3
61	Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application. *Lab on A Chip*, **2020**, 20, 3334-3345	7.2	5
60	Aneurysm-type plexiform lesions form in supernumerary arteries in pulmonary arterial hypertension: potential therapeutic implications. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2019**, 317, L805-L815	5.8	5
59	CAR, a Homing Peptide, Prolongs Pulmonary Preferential Vasodilation by Increasing Pulmonary Retention and Reducing Systemic Absorption of Liposomal Fasudil. *Molecular Pharmaceutics*, **2019**, 16, 3414-3429	5.6	8
58	Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2019**, 316, L119-L130	5.8	6
57	Repurposing rosiglitazone, a PPAR-□agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH. *Journal of Controlled Release*, **2018**, 280, 113-123	11.7	6
56	Pulmonary vascular dysfunction secondary to pulmonary arterial hypertension: insights gained through retrograde perfusion. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2018**, 314, L835-L845	5.8	7
55	Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). *Journal of Controlled Release*, **2017**, 250, 96-106	11.7	23
54	Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency. *Molecular Pharmaceutics*, **2017**, 14, 830-841	5.6	16
53	gene disruption is associated with increased hematopoietic stem cells: implication in chronic hypoxia-induced pulmonary hypertension. *American Journal of Physiology - Heart and Circulatory Physiology*, **2017**, 313, H293-H303	5.2	6
52	Inhibition of nitric oxide synthase unmasks vigorous vasoconstriction in established pulmonary arterial hypertension. *Physiological Reports*, **2017**, 5, e13537	2.6	8
51	Cyp2c44 gene disruption exacerbated pulmonary hypertension and heart failure in female but not male mice. *Pulmonary Circulation*, **2016**, 6, 360-8	2.7	11
50	Sphingosine-1-phosphate is involved in the occlusive arteriopathy of pulmonary arterial hypertension. *Pulmonary Circulation*, **2016**, 6, 369-80	2.7	24
49	How does pulmonary endarterectomy cure CTEPH: A clue to cure PAH?. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2016**, 311, L766-L769	5.8	4
48	MicroRNA-140 is elevated and mitofusin-1 is downregulated in the right ventricle of the Sugen5416/hypoxia/normoxia model of pulmonary arterial hypertension. *American Journal of Physiology - Heart and Circulatory Physiology*, **2016**, 311, H689-98	5.2	41

47	Chronic hypoxia does not cause wall thickening of intra-acinar pulmonary supernumerary arteries. *Physiological Reports*, **2016**, 4, e12674	2.6	4
46	Haemodynamic unloading reverses occlusive vascular lesions in severe pulmonary hypertension. *Cardiovascular Research*, **2016**, 111, 16-25	9.9	38
45	Hypoxia-induced glucose-6-phosphate dehydrogenase overexpression and -activation in pulmonary artery smooth muscle cells: implication in pulmonary hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2015**, 308, L287-300	5.8	47
44	Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. *Journal of Controlled Release*, **2015**, 210, 67-75	11.7	75
43	Increased reactive oxygen species, metabolic maladaptation, and autophagy contribute to pulmonary arterial hypertension-induced ventricular hypertrophy and diastolic heart failure. *Hypertension*, **2014**, 64, 1266-74	8.5	58
42	A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension. *American Journal of Pathology*, **2014**, 184, 369-75	5.8	38
41	Glucose-6-phosphate dehydrogenase plays a critical role in hypoxia-induced CD133+ progenitor cells self-renewal and stimulates their accumulation in the lungs of pulmonary hypertensive rats. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2014**, 307, L545-56	5.8	22
40	Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats. *American Journal of Physiology - Heart and Circulatory Physiology*, **2014**, 306, H243-50	5.2	58
39	Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. *Journal of Controlled Release*, **2013**, 167, 189-99	11.7	85
38	TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension. *American Journal of Pathology*, **2013**, 183, 1779-1788	5.8	31
37	Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. *American Journal of Physiology - Heart and Circulatory Physiology*, **2013**, 304, H1708-18	5.2	76
36	Endothelin-1 **2013**, 1513-1518		1
35	Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. *American Journal of Respiratory Cell and Molecular Biology*, **2011**, 45, 804-8	5.7	46
34	Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. *Circulation*, **2010**, 121, 2747-54	16.7	371
33	Rho kinase-mediated vasoconstriction in pulmonary hypertension. *Advances in Experimental Medicine and Biology*, **2010**, 661, 299-308	3.6	52
32	Role of Glucose-6-Phosphate Dehydrogenase (G6PD) in Chronic Hypoxia-induced Pulmonary Hypertension. *FASEB Journal*, **2010**, 24, 1023.2	0.9	
31	Activation of Glucose-6-Phosphate Dehydrogenase Promotes Acute Hypoxic Pulmonary Artery Contraction. *FASEB Journal*, **2010**, 24, 795.6	0.9	
30	Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2009**, 297, L1013-32	5.8	543

29	Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem. *Current Opinion in Pharmacology*, **2009**, 9, 287-96	5.1	121
28	Cellular and molecular basis of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2009**, 54, S20-S31	15.1	609
27	Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2008**, 295, L71-8	5.8	68
26	Rho kinase-mediated vasoconstriction in rat models of pulmonary hypertension. *Methods in Enzymology*, **2008**, 439, 191-204	1.7	18
25	Animal Models of Human Severe PAH. *Advances in Pulmonary Hypertension*, **2008**, 7, 346-349	0.5	
24	Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. *Circulation Research*, **2007**, 100, 923-9	15.7	284
23	Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2007**, 293, L630-8	5.8	35
22	Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2007**, 292, L885-97	5.8	145
21	Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. *Cardiovascular Research*, **2007**, 74, 377-87	9.9	67
20	Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. *Journal of Cardiovascular Pharmacology*, **2007**, 50, 697-702	3.1	56
19	Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. *Journal of Applied Physiology*, **2006**, 100, 996-1002	3.7	92
18	Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 171, 494-9	10.2	218
17	Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2004**, 287, L656-64	5.8	254
16	Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2002**, 282, L703-12	5.8	54
15	Role of endothelin-1 in lung disease. *Respiratory Research*, **2001**, 2, 90-101	7.3	170
14	Upregulation of nitric oxide synthase in mice with severe hypoxia-induced pulmonary hypertension. *Respiratory Research*, **2001**, 2, 306-13	7.3	73
13	Nitric oxide production in the hypoxic lung. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 280, L575-82	5.8	100
12	Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 280, L1040-8	5.8	46

11	Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **1999**, 277, L472-8	5.8	95
10	The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. *Journal of Clinical Investigation*, **1999**, 103, 291-9	15.9	248
9	Protein kinase G is not essential to NO-cGMP modulation of basal tone in rat pulmonary circulation. *American Journal of Physiology - Heart and Circulatory Physiology*, **1998**, 274, H672-8	5.2	16
8	Capillary recruitment and transit time in the rat lung. *Journal of Applied Physiology*, **1997**, 83, 543-9	3.7	23
7	Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. *Hepatology*, **1995**, 22, 1856-1862	11.2	54
6	Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. *The American Review of Respiratory Disease*, **1992**, 145, 793-7		138
5	Insulin-like growth factor I and protein kinase C activation stimulate pulmonary artery smooth muscle cell proliferation through separate but synergistic pathways. *Journal of Cellular Physiology*, **1990**, 144, 159-65	7	44
4	Uptake and metabolism of endothelin in the isolated perfused rat lung. *Experimental Lung Research* , **1990**, 16, 521-32	2.3	26
3	Aggregating platelets increase intracellular calcium in endothelial cells through release of adenine nucleotides. *Biochemical and Biophysical Research Communications*, **1990**, 166, 909-15	3.4	6
2	Endothelial cells in culture produce a vasoconstrictor substance. *Journal of Cellular Physiology*, **1987**, 132, 263-70	7	195
1	Pulmonary Circulation **1983**, 103-136		6